July 21, 2026
Retatrutide: What to Know About the Triple-Agonist Weight-Loss Drug
Weight loss & metabolic — designed, not prescribed.
Retatrutide is an investigational injectable medication being studied for weight loss and metabolic health. It is often called a “triple agonist” because it acts on three hormone pathways — GLP-1, GIP, and glucagon — whereas tirzepatide acts on two and semaglutide on one. Retatrutide is not FDA-approved; it remains in clinical trials, and any use is investigational and must be directed and monitored by a licensed medical provider.
What is retatrutide?
Retatrutide is an experimental medication in the same broad family as semaglutide and tirzepatide, but with a wider mechanism. By engaging GLP-1, GIP, and glucagon receptors together, it is designed to influence appetite, insulin response, and energy expenditure. It is being evaluated in ongoing clinical trials and has drawn significant attention in the weight-loss and metabolic-health community. Importantly, it has not received FDA approval, and the long-term safety and effectiveness data that support approved medications are still being gathered.
How is retatrutide different from tirzepatide and semaglutide?
The simplest distinction is the number of hormone pathways each medication targets. Semaglutide acts on one (GLP-1), tirzepatide on two (GLP-1 and GIP), and retatrutide on three (GLP-1, GIP, and glucagon). In theory, adding the glucagon pathway may affect metabolism differently, and early research has generated considerable interest. Because retatrutide is still investigational, however, it cannot be presented as proven to be better than the approved options — only as mechanistically different and still under study.
What does the research show so far?
Retatrutide has moved through early and mid-stage clinical trials, where researchers have reported meaningful average weight reduction among participants. These are trial settings with careful medical oversight, and results in a research study do not guarantee the same experience for any individual. Peer-reviewed data continue to accumulate, and larger, longer trials are needed before its full risk-benefit profile is established. We update this page as new information becomes available.
Is retatrutide safe? What about side effects?
Because retatrutide works partly like the approved GLP-1 medications, the side effects reported in trials have commonly been gastrointestinal — nausea, diarrhea, and reduced appetite — often more noticeable when starting or increasing a dose. As an investigational drug, its complete safety profile is still being characterized, which is exactly why it should only ever be considered under close medical supervision, with appropriate screening and monitoring.
How would retatrutide be accessed responsibly?
Since retatrutide is not FDA-approved, it is not available as a standard commercial prescription the way approved medications are. Any consideration of it should begin with a medical consultation that reviews your health history, goals, labs, and whether a supervised, evidence-based weight-loss plan — which may involve approved medications — is the right fit for you. At Roots, our approach starts with evaluation and physician oversight, not a one-size-fits-all product.
Frequently asked questions
Is retatrutide FDA-approved?
No. Retatrutide is investigational and remains in clinical trials. It has not been approved by the FDA for weight loss or any other use.
How is it different from Mounjaro or Ozempic?
Those contain tirzepatide and semaglutide, which are FDA-approved and act on two and one hormone pathways respectively. Retatrutide acts on three pathways and is not approved.
Can I start retatrutide at Roots?
The right first step is a medical consultation. Our providers evaluate your health and goals and discuss appropriate, supervised options with you.
This article is for general education and is not medical advice. Retatrutide is an investigational drug that is not FDA-approved; any use is experimental and must be supervised by a licensed medical provider. Individual results vary. Speak with a provider about what is appropriate for you.